麻豆官网首页入口

Aimmune Therapeutics is likely to be amongst the first company to have a drug to treat peanut allergy approved and on the market.

But since immunotherapy is more than a hundred years old, why the wait? Its chief executive Stephen Dilly says patenting a drug treatment is hard. But a patient group in the US decided enough was enough and began to fund developing a treatment itself.

Now food manufacturers and other investors are getting involved with the treatment.